Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Driving fitness assessment in cirrhosis with or without minimal hepatic encephalopathy
2009-012592-10Phase 3Active
- Sponsor
- CHU Caen Normandie
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of lactulose and levocarnitine in hepatic encephalopathy (HE) and Cirrhosis (3 arms), sponsored by CHU Caen Normandie. Primary endpoints: Sleep latency on Maintenance of Wakefulness Test, Number of lane departures on driving simulator and 1 more. Started May 2009; status: active.
02
Drugs
lactuloselevocarnitine
03
Conditions
hepatic encephalopathy (HE)Cirrhosis
Beyond the preview
Go deeper on 2009-012592-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012592-10.